A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2016
At a glance
- Drugs Sunitinib (Primary) ; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 12 Sep 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 14 Sep 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
- 10 Sep 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.